EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Sotalol Dosing and Outcomes Among Patients Undergoing Intravenous Loading for Atrial Arrhythmias—A PEAKS Registry Substudy

Benjamin A Steinberg iD, Richard Holubkov, T Jared Bunch iD, Thomas F Deering, Christopher A Groh, Robert Kennedy, Marco Perez iD, Jonathan P Piccini iD, Parash Pokharel, Salvatore J Savona, Nishant Verma iD, Kevin Watt und 1 weitere

Journal of Cardiovascular Electrophysiology · 2025

DOI: 10.1111/jce.16677 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von Benjamin A Steinberg und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Denver Health Medical Center, Denver, Colorado, USA. Hauptthemen laut MEDLINE: Sotalol, Anti-Arrhythmia Agents, Atrial Fibrillation, Heart Rate. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NHLBI NIH HHS, The PEAKs Registry was sponsored by AltaThera, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sotalol is used for the maintenance of sinus rhythm among patients with atrial fibrillation. However, there is discretion regarding dosing of chronic therapy, and the target oral dose dictates infusion doses for intravenous sotalol loading. To date, use and outcomes by dose are not well‐described.

Methods

In the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry, we analyzed outcomes among patients undergoing elective IV sotalol load for atrial arrhythmias (AT/AF). Baseline characteristics, changes in ECG parameters, in‐hospital adverse events, and arrhythmia outcomes were compared based on target oral dose (80 mg vs. 120 mg).

Results

Among 163 total patients, 85 (52%) of patients underwent loading anticipating target oral dose of 80 mg, compared with 78 (48%) for 120 mg. Those targeting 80 mg were older (median age 70 vs. 66, p < 0.001), with similar proportion female (24% vs. 21%, p = 0.71), and without significant differences in comorbidities or renal function. Patients targeted for 80 mg were less frequently kept in‐hospital for 2 oral doses after intravenous infusion (45% vs. 89%, p < 0.001). There were no significant differences in rates of sinus rhythm or adverse events during loading.

Conclusions

Selection of target oral sotalol dose (120 vs. 80 mg) does not appear to be driven by patient characteristics, and may represent an opportunity for improved treatment. In‐hospital adverse events are low overall without differences between dose. Trial Registration Clinicaltrials. gov # NCT05247320.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SotalolAnti-Arrhythmia AgentsAtrial FibrillationHeart RateHumansFemaleRegistriesMaleAgedTreatment OutcomeProspective StudiesMiddle AgedInfusions, IntravenousAdministration, OralTime FactorsAction PotentialsRisk Factors

Stichwörter der Autor:innen

antiarrhythmic drugsatrial fibrillationdosingintravenous sotalolregistry

Substanzen

SotalolAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Medicine, Denver Health Medical Center, Denver, Colorado, USA.
  • Department of Medicine, University of Colorado Anschutz Medical Campus, Aroura, Colorado, USA.
  • CPC Clinical Research, Aurora, Colorado, USA.
  • Department of Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
  • Data Coordinating Center, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
  • Piedmont Heart Institute, Atlanta, Georgia, USA.

ORCID-Profile: Benjamin A Steinberg, T Jared Bunch, Marco Perez, Jonathan P Piccini, Nishant Verma, Suneet Mittal

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS
  • The PEAKs Registry was sponsored by AltaThera, Inc.

Zitieren

APA

Steinberg, B. A., Holubkov, R., Bunch, T. J., Deering, T. F., Groh, C. A., Kennedy, R., Perez, M., Piccini, J. P., Pokharel, P., Savona, S. J., Verma, N., Watt, K., & Mittal, S. (2025). Sotalol Dosing and Outcomes Among Patients Undergoing Intravenous Loading for Atrial Arrhythmias—A PEAKS Registry Substudy. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16677

Vancouver

Steinberg BA, Holubkov R, Bunch TJ, Deering TF, Groh CA, Kennedy R, et al. Sotalol Dosing and Outcomes Among Patients Undergoing Intravenous Loading for Atrial Arrhythmias—A PEAKS Registry Substudy. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.16677

BibTeX
@article{Steinberg2025,
  author = {Steinberg, Benjamin A and Holubkov, Richard and Bunch, T Jared and Deering, Thomas F and Groh, Christopher A and Kennedy, Robert and Perez, Marco and Piccini, Jonathan P and Pokharel, Parash and Savona, Salvatore J and Verma, Nishant and Watt, Kevin and Mittal, Suneet},
  title = {Sotalol Dosing and Outcomes Among Patients Undergoing Intravenous Loading for Atrial Arrhythmias—A PEAKS Registry Substudy},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  doi = {10.1111/jce.16677}
}
Kostenlos starten →